| |
Total No.
|
Non-SVR† No. (%)
|
SVR† No. (%)
|
P value
|
|---|
|
Patient Number
|
200
|
136(68.0)
|
64(32.0)
| |
|
Gender
| | | |
NS‡
|
|
Male
|
103
|
69(70.0)
|
34(33.0)
| |
|
Female
|
97
|
67(69.1)
|
30(30.9)
| |
|
Age (year)
| |
47.6 ± 10.0
|
44.2 ± 13.5
|
NS
|
|
History of transfusion
| | | |
NS
|
|
No
|
141
|
97(68.8)
|
44(31.2)
| |
|
Yes
|
59
|
39(66.1)
|
20(33.9)
| |
|
Liver histopathology
| | | | |
|
Total score of necroinflammatory activity
|
4.10 ± 2.59
|
4.21 ± 2.31
|
NS
|
|
Fibrosis score
| | | |
<0.01
|
|
F3–4
|
70
|
57(81.4)
|
13(18.6)
| |
|
F0–2
|
130
|
79(60.8)
|
51(39.2)
| |
|
Pretreatment ALT value (IU/L)
|
87.8 ± 86.5
|
143.5 ± 153.5
|
<0.01
|
|
Pretreatment serum level of HCV RNA§
|
6.17 ± 0.61
|
5.62 ± 0.56
|
<0.0001
|
|
HCV genotype
| | | | |
|
1b
|
80
|
63(78.8)
|
17(21.3)
|
<0.01
|
|
Non-1b
|
120
|
73(60.8)
|
47(39.2)
| |
|
Interferon preparation
| | | |
NS
|
|
Recombinant IFN-α-2a
|
37
|
29(78.4)
|
8(21.6)
| |
|
Recombinant IFN-α-2b
|
95
|
62(65.3)
|
33(34.7)
| |
|
Lymphoblastoid IFN-α-n1
|
68
|
45(66.2)
|
23(33.8)
| |
|
Interferon regimen
| | | |
<0.05
|
|
3-MU group¶
|
76
|
58(76.3)
|
18(23.7)
| |
|
6-MU group¶
|
124
|
78(62.1)
|
46(37.1)
| |
- † SVR: sustained virological response.
- ‡ NS: not significant.
- §Presented as log (equivalent/mL).
- ¶ 3-MU group: interferon-α 3 million units thrice weekly for 24 weeks; 6-MU group: interferon-α 6 million units thrice weekly for 24 weeks.
